Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Day - New Shout Out...

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jul 25, 2024 12:28am

121 Views

Post# 36147363

RE:RE:RE:RE:New Day - New Shout Out...

Thanks CancerSlayer. I'd guess the Rutherrin was delivered systemically but I don't really know. I'll ask.

CancerSlayer wrote: Thanks Eoganacht...The Rutherrin-XPDT NSCLC preclinical results were very encouraging. Do you happen to know if the Rutherrin was administered systemically as clinically intended? The more closely preclinical studies emulate clinical conditions, the more meaningful the results & the higher the probability of clinical translation.

The ramifications of such positive results & the fact that they were able to achieve a complete response in one mouse (& was thus considered cancer-free) would be significantly more positive if indeed the animal received systemic Rutherrin vs more direct intratumoral injection. I'm assuming the former is the case...Thanks again for your many insightful contributions.

Eoganacht wrote: I think Theralase is ahead. But there could be any number of clinical trials going on I'm not aware of.

A recent Theralase nr reported the destruction of NSCLC in mice using X-ray activated Rutherrin, so Theralase has a solution that works.

But there may be room for improvement. XPDT overcomes the depth of penetration limitation of visible light but the difficulty is how effectively energy can be transferred from the X-Ray to the PS. Dr. McFarland and Lilge published research in 2023 which seeks to solve the problem.

They created a compound composed of a nanoparticle and a Ru-based PS. The X-rays effectively activated the nanoparticles iwhich in turn effectively activated the PS using a process known as Frster resonance energy transfer. The result is the effective generation of ROS at unlimited tissue penetration depth. (Sounds like the holy grail...)

If Theralase gets properly funded it would be great if they could work on implementing this technology.

High quantum efficiency ruthenium coordination complex photosensitizer for improved radiation-activated Photodynamic Therapy

DJDawg wrote:
Great find. One thing that I hope TLT is ahead of is finding and validating an agent that can be activated by xrays. That is a huge thing to have since light can only penetrate mm in tissue.

Eog, would that be correct? xray activation still appears to be an area where TLT is ahead?